The outcome of this election could turn health policy on its head, but one thing's fairly certain no matter who wins: PBMs will remain in the spotlight.
Why it matters: Because of the bipartisan scrutiny of PBMs, legislation that would change their business practices to lower drug costs has a better chance of advancing.
Comments